Overview

Pazopanib, Docetaxel, Prednisone Prostate

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).

Phase:

Phase 1

Details

Lead Sponsor:

Daniel George, MD

Collaborator:

GlaxoSmithKline

Treatments:

Docetaxel
Prednisone